Company Filing History:
Years Active: 2021-2024
Title: The Innovations of Robert Craig Melling
Introduction
Robert Craig Melling is a notable inventor based in Didcot, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as inhibitors for various biological pathways. With a total of 2 patents, Melling's work is recognized for its potential therapeutic applications.
Latest Patents
Melling's latest patents include a compound known as 6-pyrimidin-isoindole derivative, which acts as an ERK1/2 inhibitor. This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide. The patent details novel physical forms of the compound, a process for preparing it, synthetic intermediates for use in the process, and novel formulations containing the compound, as well as its therapeutic uses.
Career Highlights
Melling is currently associated with Otsuka Pharmaceutical Company, Limited, where he continues to innovate and contribute to the pharmaceutical industry. His work focuses on developing new therapeutic agents that can address various medical conditions.
Collaborations
Some of Melling's notable coworkers include Paul Anthony Baguley and Colin Thomas Lindley. Their collaborative efforts have likely contributed to the advancements in the projects they have worked on together.
Conclusion
Robert Craig Melling is a distinguished inventor whose work in pharmaceutical innovations has the potential to impact therapeutic practices significantly. His contributions, particularly in the development of ERK1/2 inhibitors, highlight the importance of research and innovation in medicine.